The FDA cleared AeviceMD for use in pediatric patients aged three years and above. The company says clearance marks a significant milestone in its mission to deliver continuous, home-based respiratory monitoring. It aims to bring its device to vulnerable populations, including young children with asthma and other chronic respiratory conditions.

Singapore-based Aevice designed its stethoscope for remote monitoring of lung sounds, enabling early detection of respiratory exacerbations. The device features clinically validated AI and a pediatric-friendly design to deliver objective data to monitor chronic respiratory diseases from home. As a hospital-at-home tool, AeviceMD supports earlier interventions, reduces readmissions and extends care beyond traditional settings.